查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654350

静脉免疫球蛋白市场规模、份额、趋势分析报告：按应用、通路、地区、细分市场预测，2025-2030 年

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10个工作天内

价格

静脉注射免疫球蛋白市场的成长和趋势

根据 Grand View Research, Inc. 的一份新报告，全球静脉注射免疫球蛋白市场规模预计将到 2030 年达到 210.5 亿美元，2025 年至 2030 年期间的复合年增长率为 7.2%。

在预计预测期内，免疫不全症盛行率的增加和静脉注射免疫球蛋白疗法的采用将推动市场成长。此外，免疫球蛋白的仿单标示外使用增加以及医疗领域的投资正在推动市场成长。此外，出血性疾病的增加和老龄人口的成长也是推动该行业成长的因素。

预计皮下免疫球蛋白在治疗原发性免疫力缺乏和替代疗法中的应用将越来越广泛，这将成为未来七年市场成长的基础。此外，主要市场参与企业正专注于推出创新产品以扩大其全球分销网络。例如，Octapharma US 于 2021 年 7 月获得 FDA 批准，推出该公司首个静脉注射免疫球蛋白产品 Octagam 10%，该产品推荐用于治疗成人免疫介导的发炎性疾病—皮肌炎。

目前，COVID-19 疫情已进入最后阶段，预计将推动全球静脉注射免疫球蛋白市场的发展。例如，在印度，Bharat Biotech 正在进行研究，以产生单株抗体作为 COVID-19 的潜在治疗方法。印度科学与工业研究理事会 (CSIR) 已核准该计划作为其新千禧年印度技术领导策略的一部分。此外，COVID-19 为患有精神和神经病变的患者带来了重大问题，因为他们更容易受到感染。例如，2021 年 4 月，领先的血浆衍生药物供应商 Grifols 与 NIH 和 NIAID 合作参与了一项门诊病人抗 SARS-CoV-2 高剂量静脉注射免疫球蛋白的分析研究。预计这将在预测期内促进市场成长。

主要企业正在采用策略联盟来保持竞争力。这些努力包括併购、联盟和新产品开发。例如，Grifols 的 XEMBIFY 于 2022 年 3 月在欧洲核准，增加了新药的机会。凭藉此欧洲核准，Grifols 扩大了其创新的欧洲 IG 产品组合，为患者和医疗保健专业人员提供了原发性和次发性免疫力缺乏的重要新治疗方案。 2021年2月，辉瑞获得美国FDA批准其静脉注射免疫球蛋白PANZYGA的补充生技药品核准申请(sBLA)，用于治疗患有重度发炎性去髓鞘化多发性神经病变(CIDP)的成年患者。

静脉注射免疫球蛋白市场报告重点

  • 低丙种球蛋白血症应用领域在 2024 年占据第三大收益占有率。这是由于意识层级的提高和疾病发病率的上升导致对治疗低丙种球蛋白血症的免疫球蛋白替代疗法的需求不断增加。
  • 预计预测期内专业药局将经历显着成长。医院提供便利的居家护理，对许多患者来说是个有吸引力的选择。这是因为医院网路庞大，而且透过医院药局可以轻鬆获得种类繁多的便利产品。此外，医院为许多患者提供快速的报销、治疗和适当的护理，使得选择医院药房的患者数量激增。
  • 由于专业药房能够实现居家治疗，因此预计专业药房分销管道部分将在预测期内以丰厚的复合年增长率扩张。
  • 由于拥有完善的医疗保健体系、庞大的目标人口以及患者对血浆蛋白疗法的高度认知，北美在 2024 年的销售额中占了 46.11% 的最大份额。
  • 亚太地区 IVIG 市场正在迅速扩张，这得益于免疫不全症盛行率的显着上升，尤其是在中国、印度、日本和澳洲等国家。
  • 由于医疗设施的改善、医疗支出的增加以及公众对免疫不全症的意识提高，预计印度、中国和南非等国家将在预测期内实现显着增长。
  • 预计在预测期内，川崎病领域将成为市场上成长最快的领域。

目录

第一章调查方法与范围

第 2 章执行摘要

3. 静脉注射免疫球蛋白市场变数、趋势与范围

  • 母市场展望
  • 补贴市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场问题分析
  • 静脉注射免疫球蛋白分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章静脉免疫球蛋白市场的应用、估计与趋势分析

  • 静脉注射免疫球蛋白市场：应用细分仪表板
  • 静脉注射免疫球蛋白市场：2024 年和 2030 年应用趋势分析
  • 免疫不全症
  • CIDP
  • 低丙种球蛋白血症
  • 先天性爱滋病
  • 慢性淋巴性白血病
  • 重症肌无力
  • 多灶性运动神经病变
  • 免疫球蛋白
  • 川崎病
  • 格林-巴利综合症
  • 其他的

5. 静脉注射免疫球蛋白市场按通路划分、估计和趋势分析

  • 静脉注射免疫球蛋白市场：通路细分仪表板
  • 静脉注射免疫球蛋白市场：2024 年和 2030 年通路变化分析
  • 医院药房
  • 专业药房
  • 其他的

6. 静脉注射免疫球蛋白市场区域分布、预测及趋势分析

  • 静脉注射免疫球蛋白市场占有率（按地区划分），2024 年和 2030 年，单位：百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 南非

第七章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 2024 年公司市场占有率分析
  • 2024 年企业热图分析
  • 公司简介
    • BIoTest AG.
    • Baxter.
    • Octapharma AG
    • LFB
    • Grifols SA
    • CSL.
    • China Biologics Products Inc.
    • Kedrion.
    • BDI Pharma Inc.
Product Code: 978-1-68038-800-8

Intravenous Immunoglobulin Market Growth & Trends:

The global intravenous immunoglobulin market size is estimated to reach USD 21.05 billion by 2030, expanding at a CAGR of 7.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.

The rising incorporation of subcutaneous immunoglobulin in the treatment of primary immunodeficiency diseases as well as in replacement therapy is anticipated to provide a growth platform to the market in the next seven years. Moreover, the key market players are focusing on breakthrough product introductions to expand their global distribution network. For instance, Octapharma U.S. got FDA clearance in July 2021 for Octagam 10%, its first intravenous immunoglobulin recommended for the treatment of the immune-mediated inflammatory illness known as dermatomyositis in adults.

The COVID-19 pandemic, which is currently in its last stages, is expected to boost the worldwide market for intravenous immunoglobulin. In India, for instance, Bharat Biotech is conducting a study to create monoclonal antibodies as a potential COVID-19 treatment. The Council of Scientific and Industrial Research (CSIR) has approved the project as part of its New Millennium Indian Technology Leadership strategy. Moreover, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. For instance, in April 2021, Grifols, a key provider of plasma-derived medicines, contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients. This is expected to provide a boost to the market growth in the forecast period.

Key players are adopting strategic alliances to sustain the competition. These initiatives include mergers & acquisitions, collaborations, and new product developments. For instance, in March 2022, Grifols' XEMBIFY has been approved in Europe, increasing access to novel medicines. Grifols' clearance in Europe allows it to extend its breakthrough European IG product range and offer patients and healthcare professionals another crucial therapy solution for primary and secondary immunodeficiencies. In February 2021, Pfizer gained US FDA clearance for the supplemental Biologics License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure adult patients with severe inflammatory demyelinating polyneuropathy (CIDP).

Intravenous Immunoglobulin Market Report Highlights:

  • The hypogammaglobulinemia application segment held the third-largest revenue share in 2024. This can be attributed to the increasing demand for immunoglobulin replacement therapies to treat hypogammaglobulinemia diseases, which is driven by rising awareness levels amongst patients and increasing incidences of the disease
  • Specialty pharmacy is expected to grow considerably over the forecast period. They offer the convenience of at-home treatment, making them an attractive option for many patients owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies. Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacie
  • The specialty pharmacy distribution channel segment is anticipated to expand at a lucrative CAGR during the forecast period as specialty pharmacies enable easy treatment at home
  • North America held the largest share of 46.11% in terms of revenue in 2024 due to the presence of a well-regulated healthcare system, the larger pool of target population, and high patient awareness pertinent to the plasma protein products
  • The IVIG market in Asia Pacific is expanding rapidly, driven by a significant increase in the incidence of immunodeficiency diseases, particularly in countries such as China, India, Japan, and Australia.
  • Countries such as India, China, and South Africa are expected to witness significant growth over the forecast period owing to improving healthcare facilities, rising healthcare expenditure, and growing public awareness regarding immune deficiency disorders
  • The Kawasaki disease segment is expected to exhibit the fastest growth in the market over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Intravenous Immunoglobulin (IVIG) Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of immunodeficiency diseases
      • 3.3.1.2. Increasing adoption of immunoglobulin replacement therapy
      • 3.3.1.3. Rising geriatric population
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Cost intensive nature of immunoglobulin replacement therapy
      • 3.3.2.2. Stringent regulations pertaining to production and approvals
    • 3.3.3. Market Challenge Analysis
      • 3.3.3.1. Quality assurance and standardization-related challenges
      • 3.3.3.2. Limited scope for multiple evaluations
  • 3.4. Intravenous Immunoglobulin (IVIG) Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Intravenous Immunoglobulin (IVIG) Market: By Application Estimates & Trend Analysis

  • 4.1. Intravenous Immunoglobulin (IVIG) Market: Application Segment Dashboard
  • 4.2. Intravenous Immunoglobulin (IVIG) Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Immunodeficiency Diseases
    • 4.3.1. Immunodeficiency Diseases Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4. CIDP
    • 4.4.1. CIDP Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Hypogammaglobulinemia
    • 4.5.1. Hypogammaglobulinemia Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Congenital AIDS
    • 4.6.1. Congenital AIDS Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.7. Chronic Lymphocytic Leukemia
    • 4.7.1. Chronic Lymphocytic Leukemia Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.8. Myasthenia Gravis
    • 4.8.1. Myasthenia Gravis Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.9. Multifocal Motor Neuropathy
    • 4.9.1. Multifocal Motor Neuropathy Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.10. ITP
    • 4.10.1. ITP Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.11. Kawasaki Disease
    • 4.11.1. Kawasaki Disease Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.12. Guillain-Barre Syndrome
    • 4.12.1. Guillain-Barre Syndrome Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.13. Others
    • 4.13.1. Others Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Segment Dashboard
  • 5.2. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Hospital Pharmacies
    • 5.3.1. Hospital Pharmacies Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4. Specialty Pharmacies
    • 5.4.1. Specialty Pharmacies Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Intravenous Immunoglobulin (IVIG) Market: Regional Estimates & Trend Analysis

  • 6.1. Intravenous Immunoglobulin (IVIG) Market Share, By Region, 2024 & 2030, USD Million
  • 6.2. North America
    • 6.2.1. North America Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018- 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Norway
      • 6.3.8.1. Norway Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Sweden Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2017 - 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Kuwait
      • 6.6.4.1. Kuwait Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Africa
      • 6.6.5.1. South Africa Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company Heat Map Analysis, 2024
  • 7.5. Company Profiles
    • 7.5.1. Biotest AG.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Baxter.
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. Octapharma AG
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. LFB
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. Grifols SA
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. CSL.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. China Biologics Products Inc.
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. Kedrion.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. BDI Pharma Inc.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 4 Global Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 North America Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 7 North America Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 9 U.S. Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 Canada Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 Canada Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 13 Mexico Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 Europe Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 18 Germany Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 U.K. Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 U.K. Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 France Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 22 France Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Italy Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 24 Italy Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Spain Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Spain Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Denmark Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 28 Denmark Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Sweden Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 30 Sweden Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Norway Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Norway Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 China Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 37 China Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Japan Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 39 Japan Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 India Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 India Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 South Korea Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 43 South Korea Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Australia Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 Australia Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Thailand Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Thailand Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Latin America Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 Latin America Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Brazil Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 52 Brazil Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Argentina Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 54 Argentina Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 South Africa Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 South Africa Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 UAE Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 63 UAE Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & forecasting
  • Fig. 6 Market formulation & Validation
  • Fig. 7 Intravenous Immunoglobulin, Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five forces Analysis
  • Fig. 15 Global Intravenous Immunoglobulin Market: By Application Movement Analysis
  • Fig. 16 Global Intravenous Immunoglobulin Market, for Immunodeficiency Diseases, 2018 - 2030 (USD Million)
  • Fig. 17 Global Intravenous Immunoglobulin Market, for CIDP, 2018 - 2030 (USD Million)
  • Fig. 18 Global Intravenous Immunoglobulin Market, for Hypogammaglobulinemia, 2018 - 2030 (USD Million)
  • Fig. 19 Global Intravenous Immunoglobulin Market, for Congenital AIDS, 2018 - 2030 (USD Million)
  • Fig. 20 Global Intravenous Immunoglobulin Market, for Chronic Lymphocytic Leukemia, 2018 - 2030 (USD Million)
  • Fig. 21 Global Intravenous Immunoglobulin Market, for Myasthenia Gravis, 2018 - 2030 (USD Million)
  • Fig. 22 Global Intravenous Immunoglobulin Market, for Multifocal Motor Neuropathy, 2018 - 2030 (USD Million)
  • Fig. 23 Global Intravenous Immunoglobulin Market, for ITP, 2018 - 2030 (USD Million)
  • Fig. 24 Global Intravenous Immunoglobulin Market, for Kawasaki Disease, 2018 - 2030 (USD Million)
  • Fig. 25 Global Intravenous Immunoglobulin Market, for Guillain-Barre Syndrome, 2018 - 2030 (USD Million)
  • Fig. 26 Global Intravenous Immunoglobulin Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 27 Global Intravenous Immunoglobulin Market: Distribution Channel Movement Analysis
  • Fig. 28 Global Intravenous Immunoglobulin Market, for Hospital Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global Intravenous Immunoglobulin Market, for Specialty Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Global Intravenous Immunoglobulin Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Marketplace: Key Takeaways Intravenous Immunoglobulin Market, Region 2018 - 2030 (USD Million)
  • Fig. 32 Regional Outlook, 2022 & 2030 Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 33 Global Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 34 North America Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 35 US Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 40 UK Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 41 France Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 49 China Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 50 India Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 62 Company/Competition Categorization
  • Fig. 63 Company Market Share Analysis, 2024
  • Fig. 64 Company Market Position Analysis, 2024
  • Fig. 65 Strategy Mapping